Get started
Author

Ruigang Cai

Observed names: Cai Rui-gang, Rui-Gang Cai, Rui-gang Cai, Rui‐gang Cai
ORCID: 0009-0003-1652-671X
Observed ORCID: 0009-0003-1652-671X
OpenAlex ID: A5113729720
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2017 · Fei Ma, Qiao Li, et al. · Journal of Clinical Oncology · 229
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first‐line chemotherapy of HER2‐negative metastatic breast cancer
2019 · Xiuwen Guan, Fei Ma, et al. · 癌症：英文版 · 112
PDF
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
2022 · Yiqun Li, Nilupai Abudureheiyimu, et al. · Frontiers in Oncology · 108
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
2021 · Jiayu Wang, Yunjiang Liu, et al. · Journal of Clinical Oncology · 101
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
2016 · Pin Zhang, Yi Yin, et al. · Oncotarget · 91
PDF
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
2019 · Qiao Li, Xiuwen Guan, et al. · Clinical Cancer Research · 88
Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
2014 · Qian Li, Mei Liu, et al. · PLoS ONE · 71
Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
2022 · Hangcheng Xu, Yiqun Han, et al. · Frontiers in Oncology · 66
PDF
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
2016 · Jiayu Wang, Die Sang, et al. · Medicine · 39
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer
2020 · Feng Du, Wenmiao Wang, et al. · Breast Cancer Research and Treatment · 34
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population
2018 · Bo Lan, Fei Ma, et al. · International Journal of Cancer · 31
PDF
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes
2015 · Qiao Li, Qing Li, et al. · Cancer Biology & Therapy · 30
PDF
Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China
2020 · Shaoyan Lin, Hongnan Mo, et al. · The Breast · 25
Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer
2020 · Binhe Xu, Jiayu Wang, et al. · Cancer Research · 25
Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
2018 · Meiying Li, Fei Ma, et al. · 癌症：英文版 · 23
PDF
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
2020 · Yiqun Li, Qiao Li, et al. · The Breast · 21
PDF
Polymorphisms of MTHFR and TYMS predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancer
2019 · Shaoyan Lin, Jian Yue, et al. · 癌症：英文版 · 21
PDF
Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
2019 · Anjie Zhu, Peng Yuan, et al. · Oncology Letters · 20
PDF
HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer
2014 · Jiayu Wang, Binghe Xu, et al. · The International Journal of Biological Markers · 20
Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts
2017 · Jingjing Wang, Jiayu Wang, et al. · Oncotarget · 19
PDF
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China
2018 · Bo Lan, Fei Ma, et al. · International Journal of Cancer · 17
PDF
Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis
2020 · Yiqun Han, Jiayu Wang, et al. · Clinical Breast Cancer · 16
Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China
2020 · Yimeng Chen, Yin Guan, et al. · International Journal of Cancer · 16
Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial
2015 · Jiayu Wang, Binghe Xu, et al. · Cancer · 16
PDF
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer
2013 · Yi Yin, Pin Zhang, et al. · Journal of Huazhong University of Science and Technology [Medical Sciences] · 16
Works count: 114
Citation count: 1,500
H-index: 19
I10-index: 34
Year
Topic
Type